The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy

Blood

Volumn 127, Issue 8, 2016, Pages 989-996

  Jodele, Sonata ^a   Zhang, Kejian ^a   Zou, Fanggeng ^a   Laskin, Benjamin ^b   Dandoy, Christopher E ^a   Myers, Kasiani C ^a   Lane, Adam ^a   Meller, Jaroslav ^a,c   Medvedovic, Mario ^c   Chen, Jenny ^c   Davies, Stella M ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ARTICLE; CAUCASIAN; CHILD; COMPLEMENT ACTIVATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GRAFT RECIPIENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RACE DIFFERENCE; RISK ASSESSMENT; RNA FINGERPRINTING; RNA SEQUENCE; THROMBOTIC THROMBOCYTOPENIC PURPURA; UPREGULATION; ADVERSE EFFECTS; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; HIGH THROUGHPUT SEQUENCING; INFANT; KAPLAN MEIER METHOD; PRESCHOOL CHILD; THROMBOTIC MICROANGIOPATHIES;

TRANSCRIPTOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; MALE; PROSPECTIVE STUDIES; THROMBOTIC MICROANGIOPATHIES; TRANSCRIPTOME;

EID: 84960378679     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-08-663435     Document Type: Article

References (33)

1. Jodele S, Laskin BL, Dandoy CE, et al. A new paradigm: Diagnosis and management of HSCTassociated thrombotic microangiopathy as multisystem endothelial injury. Blood Rev. 2015;29(3): 191-204.
2. Ricklin D, Cines DB. TMA: beware of complements. Blood. 2013;122(12):1997-1999.
3. Meri S. Complement activation in diseases presenting with thrombotic microangiopathy. Eur J Intern Med. 2013;24(6):496-502.
4. Chima RS, Abulebda K, Jodele S. Advances in critical care of the pediatric hematopoietic stem cell transplant patient. Pediatr Clin North Am. 2013;60(3):689-707.
5. Abboud I, Peraldi MN, Hingorani S. Chronic kidney diseases in long-term survivors after allogeneic hematopoietic stem cell transplantation: monitoring and management guidelines. Semin Hematol. 2012;49(1):73-82.
6. Laskin BL, Goebel J, Davies SM, Jodele S. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantationassociated thrombotic microangiopathy. Blood. 2011;118(6):1452-1462.
7. Cho BS, Yahng SA, Lee SE, et al. Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation. Transplantation. 2010;90(8):918-926.
8. Jodele S, Davies SM, Lane A, et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood. 2014;124(4):645-653.
9. Bu F, Maga T, Meyer NC, et al. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2014;25(1):55-64.
10. Feng S, Eyler SJ, Zhang Y, et al. Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome. Blood. 2013;122(8):1487-1493.
11. Bresin E, Rurali E, Caprioli J, et al; European Working Party on Complement Genetics in Renal Diseases. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol. 2013;24(3): 475-486.
12. Crovetto F, Borsa N, Acaia B, et al. The genetics of the alternative pathway of complement in the pathogenesis of HELLP syndrome. J Matern Fetal Neonatal Med. 2012;25(11):2322-2325.
13. Jodele S, Licht C, Goebel J, et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplantassociated thrombotic microangiopathy. Blood. 2013;122(12):2003-2007.
14. Sivakumaran TA, Husami A, Kissell D, et al. Performance evaluation of the next-generation sequencing approach for molecular diagnosis of hereditary hearing loss. Otolaryngol Head Neck Surg. 2013;148(6):1007-1016.
15. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009;25(9):1105-1111.
16. Huber W, Carey VJ, Gentleman R, et al. Orchestrating high-throughput genomic analysis with Bioconductor. Nat Methods. 2015;12(2): 115-121.
17. Anders S, McCarthy DJ, Chen Y, et al. Countbased differential expression analysis of RNA sequencing data using R and Bioconductor. Nat Protoc. 2013;8(9):1765-1786.
18. Sartor MA, Leikauf GD, Medvedovic M. LRpath: a logistic regression approach for identifying enriched biological groups in gene expression data. Bioinformatics. 2009;25(2):211-217.
19. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledgebased approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545-15550.
20. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA. 2003;100(16):9440-9445.
21. Vernon KA, Goicoechea de Jorge E, Hall AE, et al. Acute presentation and persistent glomerulonephritis following streptococcal infection in a patient with heterozygous complement factor H-related protein 5 deficiency. Am J Kidney Dis. 2012;60(1):121-125.
22. Caprioli J, Noris M, Brioschi S, et al; International Registry of Recurrent and Familial HUS/TTP. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108(4): 1267-1279.
23. Camilleri RS, Scully M, Thomas M, et al. A phenotype-genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom. J Thromb Haemost. 2012;10(9): 1792-1801.
24. Liu F, Jin J, Dong NZ, Wang YG, Ruan CG. [Identification of two novel mutations in ADAMTS13 gene in a patient with hereditary thrombotic thrombocytopenic purpura] [in Chinese]. Zhonghua Xue Ye Xue Za Zhi. 2005; 26(9):521-524.
25. Cayci FS, Cakar N, Hancer VS, Uncu N, Acar B, Gur G. Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation. Pediatr Nephrol. 2012;27(12):2327-2331.
26. Skerka C, Zipfel PF, Müller D, et al. The autoimmune disease DEAP-hemolytic uremic syndrome. Semin Thromb Hemost. 2010;36(6): 625-632.
27. Jodele S, Fukuda T, Mizuno K, et al. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation [published online ahead of print October 9, 2015]. Biol Blood Marrow Transplant. doi:10.1016/j. bbmt.2015.10.002.
28. Ermini L, Goodship TH, Strain L, et al. Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS. Mol Immunol. 2012;49(4):640-648.
29. Adriani KS, Brouwer MC, Geldhoff M, et al. Common polymorphisms in the complement system and susceptiblity to bacterial meningitis. J Infect. 2013;66(3):255-262.
30. Sprong T, Roos D, Weemaes C, et al. Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections. Blood. 2006;107(12): 4865-4870.
31. Brouwer MC, de Gans J, Heckenberg SG, Zwinderman AH, van der Poll T, van de Beek D. Host genetic susceptibility to pneumococcal and meningococcal disease: a systematic review and meta-analysis. Lancet Infect Dis. 2009;9(1):31-44.
32. Owen EP, Würzner R, Leisegang F, et al. A complement C5 gene mutation, c.754G.A:p. A252T, is common in the Western Cape, South Africa and found to be homozygous in seven percent of Black African meningococcal disease cases. Mol Immunol. 2015;64(1):170-176.
33. Baker KS, Davies SM, Majhail NS, et al. Race and socioeconomic status influence outcomes of unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009;15(12):1543-1554.